Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 54Lung Neoplasms 46Neoplasm Metastasis 36Carcinoma, Non-Small-Cell Lung 36Multiple Myeloma 26Breast Neoplasms 26Glioma 23Carcinoma, Renal Cell 22Pancreatic Neoplasms 21Melanoma 21Glioblastoma 21Lymphoma, Large B-Cell, Diffuse 20Squamous Cell Carcinoma of Head and Neck 19Ovarian Neoplasms 19Urinary Bladder Neoplasms 18Lymphoma 18Colorectal Neoplasms 18Triple Negative Breast Neoplasms 15Oropharyngeal Neoplasms 15Mouth Neoplasms 15Brain Neoplasms 15Fallopian Tube Neoplasms 13Carcinoma, Hepatocellular 13Carcinoma 13Laryngeal Neoplasms 12Astrocytoma 12Lymphoma, Follicular 11Leukemia, Myeloid, Acute 11Sarcoma 10Neuroblastoma 10

Interventions

luprolide acetate gel depot 1exemestane 1darolutamide 1X-Rays 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Leuprolide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Granulosa cell tumor of the ovary × Magnetic Resonance Spectroscopy × 90 days × Clear all
NCT06169124 2026-05-13

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
37 enrolled

Granulosa cell tumor of the ovary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡